Avalon GloboCare's Net Loss Widens to $16.2M Amid Debt Extinguishment
Ticker: ALBT · Form: 10-Q · Filed: Nov 14, 2025 · CIK: 1630212
Sentiment: bearish
Topics: Biotech, Diagnostics, Cellular Therapy, Financial Distress, Small Cap, Debt Extinguishment, Shareholder Dilution
TL;DR
**ALBT is burning cash and diluting shareholders to stay afloat, avoid this speculative biotech play.**
AI Summary
Avalon GloboCare Corp. (ALBT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $16,194,977, a substantial rise from $5,178,739 in the same period of 2024. This was primarily driven by a $9,076,587 loss on extinguishment of debt and a sharp increase in professional fees to $4,416,074 from $1,190,125. Real property rental revenue saw a modest increase to $1,050,305 for the nine months ended September 30, 2025, up from $987,634 in 2024. The company's cash position significantly decreased from $2,856,309 at December 31, 2024, to $333,931 at September 30, 2025. Total assets declined from $20,985,178 to $9,128,455, largely due to the sale of equity method investments. The company also converted convertible notes payable and accrued interest into common stock, totaling $1,587,722 in non-cash financing activities. Strategic outlook includes continued marketing of the KetoAir breathalyzer and advancing its intellectual property portfolio in cellular therapy.
Why It Matters
Avalon GloboCare's substantial net loss of $16.2 million and dwindling cash reserves to $333,931 signal significant financial distress, raising red flags for investors. The company's strategy of converting debt to equity, while reducing liabilities, dilutes existing shareholders and reflects an inability to meet cash obligations. This financial instability could impact ALBT's ability to fund its cellular therapy and diagnostic product development, potentially hindering innovation and competitive positioning against larger, better-capitalized biotech firms. Employees may face job insecurity, and customers could see disruptions in product development or support if the financial situation deteriorates further, impacting the broader market's confidence in small-cap biotech ventures.
Risk Assessment
Risk Level: high — Avalon GloboCare's net loss surged to $16,194,977 for the nine months ended September 30, 2025, from $5,178,739 in 2024, and cash plummeted from $2,856,309 to $333,931. The company also reported a total stockholders' deficit of $4,493,019, indicating liabilities exceed assets, which are clear signs of high financial risk.
Analyst Insight
Investors should exercise extreme caution and consider divesting from ALBT given the significant net losses, declining cash reserves, and negative equity. The company's reliance on debt-to-equity conversions suggests a precarious financial position that may lead to further dilution or operational challenges.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $1,050,305
- operating Margin
- N/A
- total Assets
- $9,128,455
- total Debt
- $13,621,474
- net Income
- -$16,194,977
- eps
- N/A
- gross Margin
- N/A
- cash Position
- $333,931
- revenue Growth
- +6.3%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Real property rental revenue | $1,050,305 | +6.3% |
Key Numbers
- $16.2M — Net Loss (Increased from $5.2M in 2024 for the nine months ended September 30, 2025)
- $333,931 — Cash (Decreased from $2,856,309 at December 31, 2024)
- $9,076,587 — Loss on extinguishment of debt (Significant expense for the nine months ended September 30, 2025)
- $4,416,074 — Professional fees (Increased from $1,190,125 for the nine months ended September 30, 2025)
- $1,050,305 — Real property rental revenue (Increased from $987,634 for the nine months ended September 30, 2025)
- $9,128,455 — Total Assets (Decreased from $20,985,178 at December 31, 2024)
- $4,493,019 — Total (Deficit) Equity (Negative equity at September 30, 2025, down from $7,102,623 at December 31, 2024)
- 4,252,009 — Common shares outstanding (As of November 13, 2025, indicating potential dilution)
- $1,587,722 — Conversion of convertible note payable and accrued interest into common stock (Non-cash financing activity for the nine months ended September 30, 2025)
- 98.5% — Occupancy rate of real estate building (As of September 30, 2025, indicating stable rental income)
Key Players & Entities
- Avalon GloboCare Corp. (company) — registrant
- ALBT (company) — ticker symbol
- Qi Diagnostics Limited (company) — owner and manufacturer of KetoAir breathalyzer
- U.S. Food and Drug Administration (regulator) — registered KetoAir as a Class I medical device
- Avalon Healthcare System, Inc. (company) — subsidiary of Avalon GloboCare Corp.
- Avalon (Shanghai) Healthcare Technology Co., Ltd. (company) — wholly foreign-owned enterprise of AHS
- Avalon RT 9 Properties, LLC (company) — subsidiary owning real estate
- Nasdaq Capital Market (market) — exchange where common stock is registered
- Delaware (state) — state of incorporation for Avalon GloboCare Corp.
- New Jersey (state) — location of Avalon RT 9 Properties, LLC
FAQ
What caused Avalon GloboCare Corp.'s net loss to increase significantly in Q3 2025?
Avalon GloboCare Corp.'s net loss increased significantly due to a $9,076,587 loss on extinguishment of debt and a rise in professional fees to $4,416,074 for the nine months ended September 30, 2025.
How has Avalon GloboCare Corp.'s cash position changed as of September 30, 2025?
Avalon GloboCare Corp.'s cash position decreased substantially from $2,856,309 at December 31, 2024, to $333,931 at September 30, 2025, reflecting significant cash burn from operating activities.
What is Avalon GloboCare Corp.'s strategy regarding its intellectual property and product development?
Avalon GloboCare Corp. continues to focus on advancing its intellectual property portfolio through existing patent applications and is marketing the KetoAir breathalyzer device, a Class I medical device registered with the U.S. Food and Drug Administration.
What are the key risks for investors in Avalon GloboCare Corp. based on this 10-Q filing?
Key risks include a substantial net loss of $16,194,977, a negative total stockholders' deficit of $4,493,019, and a significant decrease in cash to $333,931, all indicating severe financial instability and potential for further dilution.
How does the sale of equity method investments impact Avalon GloboCare Corp.'s balance sheet?
The sale of equity method investments contributed to a decrease in total non-current assets from $17,748,680 at December 31, 2024, to $7,039,422 at September 30, 2025, and generated $788,500 in proceeds from the sale.
What is the status of Avalon GloboCare Corp.'s real estate operations?
Avalon GloboCare Corp. owns and operates commercial real estate at its headquarters in Freehold, NJ, through Avalon RT 9 Properties, LLC, which reported a 98.5% occupancy rate as of September 30, 2025, generating $1,050,305 in rental revenue for the nine months ended September 30, 2025.
Has Avalon GloboCare Corp. issued new shares, and what was the impact?
Yes, Avalon GloboCare Corp. issued 1,302,609 common shares through the conversion of convertible notes payable and accrued interest, and 121,200 common shares from the sale of common stock and warrants, contributing to an increase in common shares outstanding and potential dilution.
What is the significance of the 'loss on extinguishment of debt' for Avalon GloboCare Corp.?
The $9,076,587 loss on extinguishment of debt indicates that the company settled debt obligations at a cost higher than their carrying value, contributing significantly to the overall net loss for the nine months ended September 30, 2025.
What is Avalon GloboCare Corp.'s current status regarding its preferred stock?
As of September 30, 2025, Avalon GloboCare Corp. had 3,800 shares of Series C Convertible Preferred Stock and 5,000 shares of Series D Convertible Preferred Stock outstanding, with Series A and B Preferred Stock having been exchanged or extinguished.
What regulatory filings has Avalon GloboCare Corp. made recently?
Avalon GloboCare Corp. filed a Form 10-Q for the quarterly period ended September 30, 2025, on November 14, 2025, and confirmed it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Risk Factors
- Deteriorating Financial Position [high — financial]: The company's net loss significantly increased to $16,194,977 for the nine months ended September 30, 2025, up from $5,178,739 in the prior year. This was exacerbated by a $9,076,587 loss on extinguishment of debt and a sharp rise in professional fees to $4,416,074. The cash position plummeted from $2,856,309 at December 31, 2024, to $333,931 at September 30, 2025.
- Asset and Equity Erosion [high — financial]: Total assets decreased from $20,985,178 to $9,128,455, primarily due to the sale of equity method investments. The company now has a total deficit equity of $4,493,019, a significant decline from $7,102,623 at the end of 2024, indicating a negative net worth.
- Increased Debt and Dilution Risk [medium — financial]: Convertible notes payable and accrued interest totaling $1,587,722 were converted into common stock, increasing the number of outstanding shares to 4,252,009 as of November 13, 2025. This conversion, along with existing debt, poses a risk of further dilution to existing shareholders.
- High Professional Fees [medium — operational]: Professional fees more than tripled, rising from $1,190,125 to $4,416,074 for the nine months ended September 30, 2025. This substantial increase in operational costs without a corresponding revenue surge impacts profitability.
- Dependence on Product Success [medium — market]: The company's strategic outlook relies on the continued marketing of the KetoAir breathalyzer and advancing its intellectual property in cellular therapy. The success of these initiatives is critical for future revenue generation and financial stability.
- Cellular Therapy IP Advancement [low — regulatory]: Advancing intellectual property in cellular therapy involves navigating complex regulatory pathways and significant research and development investment. Delays or failures in this area could impact future growth prospects.
Industry Context
Avalon GloboCare operates in the healthcare technology and real estate sectors. The healthcare technology space is characterized by rapid innovation, significant R&D investment, and complex regulatory hurdles, particularly in areas like cellular therapy. The real estate segment, focused on rental income, is generally more stable but sensitive to economic conditions and property management efficiency.
Regulatory Implications
The company's focus on cellular therapy necessitates adherence to stringent FDA and other health authority regulations for research, development, and eventual commercialization. Any delays or failures in regulatory approval processes could significantly impact the company's future prospects and financial viability.
What Investors Should Do
- Monitor cash burn rate and future financing needs.
- Evaluate the commercial viability of KetoAir and cellular therapy pipeline.
- Assess the impact of increased professional fees on profitability.
- Analyze the terms and potential dilution from outstanding convertible notes.
Key Dates
- 2025-09-30: Nine months ended September 30, 2025 financial results reported — Revealed a significant increase in net loss and a sharp decline in cash and total assets.
- 2024-12-31: Year-end financial position reported — Provided the baseline for comparison, showing $2,856,309 in cash and $20,985,178 in total assets.
- 2025-11-13: Common shares outstanding reported as 4,252,009 — Indicates potential dilution from previous periods due to stock conversions.
Glossary
- Loss on extinguishment of debt
- A loss recognized when a company repays or retires debt before its scheduled maturity date, often involving premium payments or unamortized issuance costs. (A significant $9,076,587 loss in this category heavily contributed to the increased net loss for the period.)
- Equity method investments
- An accounting method where an investment in another company is recorded at cost and adjusted for the investor's share of the investee's net income or loss. (The sale of these investments led to a substantial decrease in Avalon GloboCare's total assets.)
- Convertible note payable
- A debt instrument that can be converted into a predetermined amount of the issuer's equity (common stock) at the option of the holder. (Conversion of these notes into common stock is a non-cash financing activity that impacts the equity structure and share count.)
- Deficit Equity
- A situation where a company's liabilities exceed its assets, resulting in a negative equity balance. (Avalon GloboCare reported a deficit equity of $4,493,019, indicating financial distress.)
- Operating lease right-of-use assets
- An asset recognized under ASC 842 for the right to use an underlying asset for the lease term. (These assets are part of the company's non-current assets, reflecting its leasing arrangements.)
Year-Over-Year Comparison
Compared to the prior year's nine-month period, Avalon GloboCare has experienced a significant deterioration in its financial performance. Net loss has more than tripled, driven by a substantial loss on debt extinguishment and a sharp increase in professional fees. While real property rental revenue saw a modest increase, it was insufficient to offset the escalating expenses. The company's balance sheet reflects this strain, with total assets nearly halved and cash reserves drastically reduced, alongside a growing deficit in equity.
Filing Stats: 4,768 words · 19 min read · ~16 pages · Grade level 19.4 · Accepted 2025-11-14 17:17:57
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ALBT The Nasdaq Capital Marke
Filing Documents
- ea0264554-10q_avalon.htm (10-Q) — 1814KB
- ea026455401ex31-1_avalon.htm (EX-31.1) — 11KB
- ea026455401ex31-2_avalon.htm (EX-31.2) — 11KB
- ea026455401ex32-1_avalon.htm (EX-32.1) — 4KB
- ea026455401ex32-2_avalon.htm (EX-32.2) — 4KB
- 0001213900-25-111067.txt ( ) — 9589KB
- albt-20250930.xsd (EX-101.SCH) — 91KB
- albt-20250930_cal.xml (EX-101.CAL) — 58KB
- albt-20250930_def.xml (EX-101.DEF) — 454KB
- albt-20250930_lab.xml (EX-101.LAB) — 799KB
- albt-20250930_pre.xml (EX-101.PRE) — 478KB
- ea0264554-10q_avalon_htm.xml (XML) — 1115KB
– Financial Information
Part I – Financial Information
Financial Statements
Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets – At September 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) – For the Three and Nine Months Ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Changes in (Deficit) Equity (Unaudited) — For the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Nine Months Ended September 30, 2025 and 2024 5 Notes to Unaudited Condensed Consolidated Financial Statements 6
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 37
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 46
Controls and Procedures
Item 4. Controls and Procedures 46
– Other Information
Part II – Other Information
Legal Proceedings
Item 1. Legal Proceedings 47
Risk Factors
Item 1A. Risk Factors 47
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 48
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 48
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 48
Other Information
Item 5. Other Information 48
Exhibits
Item 6. Exhibits 49 Exhibit Index 49
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. AVALON GLOBOCARE CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 333,931 $ 2,856,309 Rent receivable 87,317 80,829 Receivable from sale of equity method investment 1,028,500 - Prepaid expense and other current assets 639,285 299,360 Total Current Assets 2,089,033 3,236,498 NON-CURRENT ASSETS: Operating lease right-of-use assets, net 83,490 4,709 Property and equipment, net 6,355 12,912 Investment in real estate, net 6,932,074 7,022,721 Equity method investments, net - 10,636,544 Other non-current assets 17,503 71,794 Total Non-current Assets 7,039,422 17,748,680 Total Assets $ 9,128,455 $ 20,985,178 LIABILITIES AND (DEFICIT) EQUITY CURRENT LIABILITIES: Accrued professional fees $ 1,320,286 $ 611,462 Accrued research and development fees 153,772 153,772 Accrued payroll liability and compensation 827,524 501,258 Accrued litigation settlement 363,450 373,450 Accrued liabilities and other payables 201,067 434,117 Accrued liabilities and other payables - related parties 100,000 732,916 Operating lease obligation, current portion 71,691 10,709 Advance from pending sale of noncontrolling interest - related party 3,158,078 3,108,106 Derivative liability 100,423 127,545 Stock subscription liability 150,000 - Note payable, net 5,797,466 5,715,447 Convertible note payable, net 1,359,918 2,113,773 Total Current Liabilities 13,603,675 13,882,555 NON-CURRENT LIABILITIES: Operating lease obligation, noncurrent portion 17,799 - Total Non-current Liabilities 17,799 - Total Liabilities 13,621,474 13,882,555 Commitments and Contingencies (Note 15) (DEFICIT) EQUITY: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; Series A Convertible Preferred Stock, 0 and 9,000 shares issued and outstanding at September 30, 202